story of the week
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
N. Engl. J. Med 2016 Oct 07;[EPub Ahead of Print], GN Hortobagyi, SM Stemmer, HA Burris, YS Yap, GS Sonke, S Paluch-Shimon, M Campone, KL Blackwell, F André, EP Winer, W Janni, S Verma, P Conte, CL Arteaga, DA Cameron, K Petrakova, LL Hart, C Villanueva, A Chan, E Jakobsen, A Nusch, O Burdaeva, EM Grischke, E Alba, E Wist, N Marschner, AM Favret, D Yardley, T Bachelot, LM Tseng, S Blau, F Xuan, F Souami, M Miller, C Germa, S Hirawat, J O'ShaughnessyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.